Our study aimed to build on these results, incorporating data published in the interim and using multivariate techniques to account for these potential confounding variables, in order to make a more definitive statement about the effect of IDH mutations independently on patient outcomes in chondrosarcoma. This evidence concerns the gene IDH2 and chondrosarcoma.